Clinical Dose Preparation of [177Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [177Lu]LuCl3 for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression-Reference-Cited by-同舟云学术

Clinical Dose Preparation of [¹⁷⁷Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [¹⁷⁷Lu]LuCl₃ for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression

Published:2022-06-01 Issue:5 Volume:37 Page:384-402
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Menon Sreeja Raj¹²,Mitra Arpit³,Chakraborty Avik²⁴,Tawate Megha⁴,Sahu Sudeep⁴,Rakshit Sutapa⁴,Gaikwad Sujay²⁴,Dhotre Geetanjali⁵,Damle Archana²⁴,Banerjee Sharmila²⁶^ORCID

Affiliation:

1. Health Physics Division, Bhabha Atomic Research Centre, Mumbai, India.

2. Homi Bhabha National Institute, Mumbai, India.

3. Medical Cyclotron Facility, Board of Radiation and Isotope Technology, Mumbai, India.

4. Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India.

5. Department of Chemical Sciences, Tata Institute of Fundamental Research, Mumbai, India.

6. Radiological Research Unit, Advance Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/cbr.2021.0230

Reference56 articles.

1. Cancer radioimmunotherapy

2. Targeted radioimmunotherapy: the role of 131I-chTNT-1/B mAb (Cotara®) for treatment of high-grade gliomas

3. Clinical radioimmunotherapy

4. Radioimmunotherapy of human tumours

5. Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer;European Journal of Nuclear Medicine and Molecular Imaging;2024-02-20

2. Intricacies in the Preparation of Patient Doses of [177Lu]Lu-Rituximab and [177Lu]Lu-Trastuzumab Using Low Specific Activity [177Lu]LuCl3: Methodological Aspects;Molecular Imaging and Biology;2023-09-06